Compare PubMatic Inc (PUBM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs TransMedics Group Inc — how do they compare? PubMatic Inc trades at $18.64 (market cap $850.88M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 3.2× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and TransMedics Group Inc for 24 Days on average.
| PUBM | TMDX | |
|---|---|---|
Market Cap | $850.88M | $2.74B |
Volume | 997,698 | 949,331 |
Sector | Technology | Health |
52-Week High | $19.18 | $150.42 |
52-Week Low | $6.28 | $61.99 |
Typical Hold Time | 40 Days | 24 Days |
Enterprise Value | $754.01M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $18.68, up 0.59% with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with revenue growth of 11% year-over-year and an EPS beat, though profitability remains challenged with negative net margins. Recent leadership appointments and AI product developments signal strategic focus on growth. Analyst consensus is bullish with 11 buy ratings and a $19.89 price target, representing 6.5% upside potential.
The stock presents a growth opportunity in digital advertising technology with AI-driven products gaining traction, but faces execution risks amid negative profitability and competitive pressures. Revenue growth acceleration and margin improvement will be critical for sustained upside, while current valuation multiples remain elevated relative to earnings performance.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
